DEC 10TH
4:30PM- 6:30PM
SAN ANTONIO, TEXAS, USA
UNDERSTANDING
THE CHALLENGE
Join a World-Class Scientific Exchange on Breast Cancer
This exclusive event brings together leading minds in breast cancer research and treatment for an expert-led discussion on the latest updates in HER2+, HR+/luminal disease, and ctDNA. Attendees will gain first-hand insights into groundbreaking data and evolving clinical strategies that are shaping the future of patient care.
Guided by Top-Tier Global Experts
The session will be chaired by internationally recognized Key Opinion Leaders:
-
Dr. Javier Cortés, Head of the International Breast Cancer Center (IBCC), Barcelona and Madrid, Spain
-
Dr. Antonio Llombart, Head of the Medical Oncology Service at Arnau de Vilanova Hospital, Valencia, Spain
-
Dr. Naoto Ueno, Director of the University of Hawaiʻi Cancer Center
These renowned experts will set the stage for a dynamic, multi-expert conversation where diverse perspectives converge to address key clinical trials, unmet needs, and future directions in breast cancer care.
The event will be moderated by Dr. Giampaolo Bianchini, leading specialist in breast oncology in the Department of Clinical Oncology at the Ospedale San Raffaele.
An Open Discussion with Leading Voices
Beyond the main presentations, the event will feature an open discussion with additional top-tier experts, creating a truly interactive forum. This collaborative exchange will allow participants to hear contrasting viewpoints, share experiences, and explore innovative approaches to improving patient outcomes.
.png)
About MEDSIR
A new model for collaborative research in clinical oncology
MEDSIR has more than a decade of experience developing strategic clinical trials in oncology, by combining the medical knowledge of our KOLs network, with a multidisciplinary expertise in clinical trials. Our innovative strategies lead to the generation of groundbreaking collaborative trials that respond to unmet clinical need while complementing the internal development program of your drug.
"
WE WANT TO IMPROVE THE LIVES OF CANCER PATIENTS BY ENSURING THEY HAVE ACCESS TO THE BEST TREATMENT OPTIONS FOR THEIR DISEASE.
